[en] Context: Method-specific reference intervals (RIs) determine utility of IGF-I as a biomarker in GH-related diseases. Differences between populations might affect applicability of RIs.
Objective: To compare population-specific RIs derived from IGF-I routine testing in laboratories in the United States and Europe using the same assay.
Design and setting: Uncensored routine IGF-I testing results generated over 5 years in 4 accredited laboratories (US, n = 778 173 males/710 752 females; Europe, n = 23 220 males/40 183 females).
Main outcome measures: Construction of RIs by indirect statistical methods designed to use routine testing data (modified Hoffmann approach). Comparison to published RIs, between the US and Europe, and between regions in the United States with lower and higher mean body mass indexes (BMIs).
Results: Lower limits (LLs) of RIs calculated from all routine data sets do not differ from the published LLs. The same is true for upper limits (ULs) calculated from European routine data. ULs derived from US routine data are significantly higher (children, 10-18 years [mean, %]: boys + 149.3 ng/mL [+34.6%]; girls + 94.9 ng/mL [+19.8%]); adults (19-95 years: males + 45 ng/mL [+20.3%]; and females + 29.7 ng/mL [+13.8%]). Average IGF-I is higher in samples from Colorado (lower mean BMI) compared with Alabama (P < 0.0001), although the difference is smaller than between each of them and Europe.
Conclusions: We provide evidence that in large datasets from the same population, direct sampling and the indirect Hoffmann approach provide comparable RIs. Although LLs are comparable between Europe and the United States, the UL is significantly higher in the United States. We suggest use of adapted RIs for the United States.
Disciplines :
Immunology & infectious disease
Author, co-author :
Bidlingmaier, Martin ; Endocrine Laboratory, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, 80336 Munich, Germany
Valcour, Andre; Laboratory Corporation of America Holdings, Burlington, 27215 North Carolina, USA
Schilbach, Katharina ; Endocrine Laboratory, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, 80336 Munich, Germany
Kuehnle, Tim; Endocrine Laboratory, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, 80336 Munich, Germany
Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, Chernausek SD, Savage MO, Wit JM, 2007 ISS Consensus Workshop participants. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. The Journal of clinical endocrinology and metabolism. 2008;93(11):4210-7. 10.1210/jc.2008-0509
Melmed S, Bronstein MD, Chanson P, et al. A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552-561. doi:10.1038/s41574-018-0058-5.
Ho KK; 2007 GH Deficiency Consensus Workshop Participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol. 2007;157(6):695-700. doi:10.1530/EJE-07-0631.
Frystyk J, Freda P, Clemmons DR. The current status of IGF-I assays - A 2009 update. Growth Hormone & IGF Research 2010;20(1):8-18.
Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem. 2011;57(4):555-559. doi:10.1373/clinchem.2010.150631.
Chanson P, Arnoux A, Mavromati M, et al. Reference values for IGF-I serum concentrations: comparison of six immunoassays. J Clin Endocrinol Metab. 2016;101(9):3450-3458.
Bidlingmaier M, Friedrich N, Emeny RT, et al. Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab. 2014;99(5):1712-1721. doi:10.1210/jc.2013-3059.
Collett-Solberg PF, Ambler G, Backeljauw PF, et al. Diagnosis, genetics, and therapy of short stature in children: a Growth Hormone Research Society International Perspective. Hormone research in paediatrics 2019;92(1):1-14. doi:10.1159/000502231.
Sklar CA, Antal Z, Chemaitilly W, et al. Hypothalamic-pituitary and growth disorders in survivors of childhood cancer: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(8):2761-2784. doi:10.1210/jc.2018-01175.
Katznelson L, Laws ER Jr., Melmed S, et al. Acromegaly: an Endocrine Society Clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933-3951.
Tumati S, Burger H, Martens S, van der Schouw YT, Aleman A. Association between cognition and serum insulin-like growth factor-1 in middle-aged & older men: an 8 year follow-up study. PLoS One. 2016;11(4):e0154450-e0154450. doi:10.1371/journal.pone.0154450.
Strasburger CJ, Vanuga P, Payer J, et al. MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults. Eur J Endocrinol. 2017;176(3):283-294.
Johannsson G, Feldt-Rasmussen U, Håkonsson IH, et al. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial. Eur J Endocrinol. 2018;178(5):491-499.
Sävendahl L, Battelino T, Brod M, et al. Once-weekly somapacitan vs daily GH in children with GH deficiency: results from a randomized phase 2 trial. J Clin Endocrinol Metab. 2020;105(4):e1847-e1861.
Rasmussen MH, Janukonyté J, Klose M, et al. Reversible albumin-binding GH possesses a potential once-weekly treatment profile in adult growth hormone deficiency. J Clin Endocrinol Metab. 2016;101(3):988-998. doi:10.1210/jc.2015-1991.
Brabant G, Wallaschofski H. Normal levels of serum IGF-I: determinants and validity of current reference ranges. Pituitary 2007;10(2):129-133. doi:10.1007/s11102-007-0035-9.
Nguyen TV, Nelson AE, Howe CJ, et al. Within-subject variability and analytic imprecision of insulinlike growth factor axis and collagen markers: implications for clinical diagnosis and doping tests. Clin Chem. 2008;54(8):1268-1276. doi:10.1373/clinchem.2008.105726.
Hawkes CP, Grimberg A. Insulin-like growth factor-i is a marker for the nutritional state. Pediatric endocrinology reviews: PER 2015;13(2):499-511.
Kord-Varkaneh H, Rinaldi G, Hekmatdoost A, et al. The influence of vitamin D supplementation on IGF-1 levels in humans: a systematic review and meta-analysis. Ageing Res Rev. 2020;57:100996. doi:10.1016/j.arr.2019.100996.
Bagg W, Aoina J, Cross PA, et al. Serum IGF-I levels are similar in Samoan, Maori and European populations despite differences in body composition. Growth Horm. IGF Res. 2006;16(1):57-60.
Gapstur SM, Kopp P, Chiu BC, Gann PH, Colangelo LA, Liu K. Longitudinal associations of age, anthropometric and lifestyle factors with serum total insulin-like growth factor-I and IGF binding protein-3 levels in Black and White men: the CARDIA Male Hormone Study. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2004;13(12):2208-2216.
Platz EA, Pollak MN, Rimm EB, et al. Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 1999;8(12):1107-1110.
McGreevy K, Hoel B, Lipsitz S, Bissada N, Hoel D. Racial and anthropometric differences in plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein-3. Urology 2005;66(3):587-592. doi:10.1016/j.urology.2005.03.070.
DeLellis K, Rinaldi S, Kaaks RJ, Kolonel LN, Henderson B, Le Marchand L. Dietary and lifestyle correlates of plasma insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3): The Multiethnic Cohort. Cancer Epidemiol. Biomark. Prev. 2004;13(9):1444-1451.
Fowke JH, Matthews CE, Yu H, et al. Racial differences in the association between body mass index and serum IGF1, IGF2, and IGFBP3. Endocr Relat Cancer. 2010;17(1):51-60. doi:10.1677/ERC-09-0023.
Maskarinec G, Williams AE, Kaaks R. A cross-sectional investigation of breast density and insulin-like growth factor I. Int J Cancer. 2003;107(6):991-996. doi:10.1002/ijc.11505.
Erotokritou-Mulligan I, Bassett EE, Cowan DA, et al. Influence of ethnicity on IGF-I and procollagen III peptide (P-III-P) in elite athletes and its effect on the ability to detect GH abuse. Clin. Endocrinol. 2009;70(1):161-168.
Berrigan D, Potischman N, Dodd KW, et al. Race/ethnic variation in serum levels of IGF-I and IGFBP-3 in US adults. Growth Horm IGF Res. 2009;19(2):146-155. doi:10.1016/j.ghir.2008.08.005.
Heald AH, Cade JE, Cruickshank JK, Anderson S, White A, Gibson JM. The influence of dietary intake on the insulin-like growth factor (IGF) system across three ethnic groups: a population-based study. Public Health Nutr. 2003;6(2):175-180. doi:10.1079/PHN2002414.
Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev. 1994;15(1):80-101. doi:10.1210/edrv-15-1-80.
Underwood LE, Thissen JP, Lemozy S, Ketelslegers JM, Clemmons DR. Hormonal and nutritional regulation of IGF-I and its binding proteins. Horm Res. 1994;42(4-5):145-151. doi:10.1159/000184187.
Isley WL, Underwood LE, Clemmons DR. Dietary components that regulate serum somatomedin-C concentrations in humans. J Clin Invest. 1983;71(2):175-182. doi:10.1172/jci110757.
Isley WL, Underwood LE, Clemmons DR. Changes in plasma somatomedin-C in response to ingestion of diets with variable protein and energy content. JPEN J Parenter Enteral Nutr. 1984;8(4):407-411. doi:10.1177/0148607184008004407.
Kaklamani VG, Linos A, Kaklamani E, Markaki I, Koumantaki Y, Mantzoros CS. Dietary fat and carbohydrates are independently associated with circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 concentrations in healthy adults. J. Clin. Oncol. 1999;17(10):3291-3298.
Larsson SC, Wolk K, Brismar K, Wolk A. Association of diet with serum insulin-like growth factor I in middle-aged and elderly men. Am J Clin Nutr. 2005;81(5):1163-1167. doi:10.1093/ajcn/81.5.1163.
Holmes MD, Pollak MN, Willett WC, Hankinson SE. Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2002;11(9):852-861.
Hoppe C, Molgaard C, Juul A, Michaelsen KF. High intakes of skimmed milk, but not meat, increase serum IGF-I and IGFBP-3 in eight-year-old boys. Eur J Clin Nutr. 2004;58(9):1211-1216.
Lieberman HR, Fulgoni VL, III, Agarwal S, Pasiakos SM, Berryman CE. Protein intake is more stable than carbohydrate or fat intake across various US demographic groups and international populations. Am J Clin Nutr. 2020;112(1):180-186.
Wittig F, Hummel E, Wenzler G, Heuer T. Energy and macronutrient intake over the course of the day of German adults: A DEDIPAC-study. Appetite 2017;114:125-136. doi:10.1016/j.appet.2017.03.018.
Amrein K, Scherkl M, Hoffmann M, et al. Vitamin D deficiency 2.0: an update on the current status worldwide. Eur J Clin Nutr. 2020;74(11):1498-1513. doi:10.1038/s41430-020-0558-y.
Jones GRD, Haeckel R, Loh TP, et al; Intervals obotICoR. Limits D. Indirect methods for reference interval determination - review and recommendations. Clinical Chemistry and Laboratory Medicine (CCLM). 2019;57(1):20-29.
Bidlingmaier M, Valcour A, Schilbach K, Kuehnle T, Diederich S, Rogge T, Cavalier E, Katayev A. Bidlingmaier-Differences in IGF-I between EU and US populations-supplemental materials.pdf. figshare; 2021:Online resource. doi:10.6084/m9.figshare.17138375.v4.
Katayev A, Fleming JK, Luo D, Fisher AH, Sharp TM. Reference intervals data mining: no longer a probability paper method. Am J Clin Pathol. 2015;143(1):134-142. doi:10.1309/AJCPQPRNIB54WFKJ.
Cole TJ, Green PJ. Smoothing reference centile curves: the LMS method and penalized likelihood. Stat Med. 1992;11(10):1305-1319. doi:10.1002/sim.4780111005.
Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth hormone & IGF research: official journal of the Growth Hormone Research Society and the International IGF Research Society 2003;13(4):113-170.
Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clinical endocrinology 2007;67(1):65-70. doi:10.1111/j.1365-2265.2007.02836.x.
Algeciras-Schimnich A, Bruns DE, Boyd JC, Bryant SC, La Fortune KA, Grebe SK. Failure of current laboratory protocols to detect lot-to-lot reagent differences: findings and possible solutions. Clin Chem. 2013;59(8):1187-1194. doi:10.1373/clinchem.2013.205070.
Ameri P, Giusti A, Boschetti M, et al. Vitamin D increases circulating IGF1 in adults: potential implication for the treatment of GH deficiency. Eur J Endocrinol. 2013;169(6):767-772. doi:10.1530/EJE-13-0510.
Lewitt MS, Dent MS, Hall K. The insulin-like growth factor system in obesity, insulin resistance and type 2 diabetes mellitus. Clin. Med. 2014;3(4):1561-1574. doi:10.3390/jcm3041561.
Frystyk J, Vestbo E, Skjaerbaek C, Mogensen CE, Orskov H. Free insulin-like growth factors in human obesity. Metab Clin Exp. 1995;44(10 Suppl 4):37-44. doi:10.1016/0026-0495(95)90219-8.
Ricart W, Fernandez-Real JM. No decrease in free IGF-I with increasing insulin in obesity-related insulin resistance. Obesity research 2001;9(10):631-636. doi:10.1038/oby.2001.83.
Maccario M, Ramunni J, Oleandri SE, et al. Relationships between IGF-I and age, gender, body mass, fat distribution, metabolic and hormonal variables in obese patients. Int. J. Obes. 1999;23(6):612-618.
Janssen F, Bardoutsos A, Vidra N. Obesity prevalence in the long-term future in 18 European Countries and in the USA. Obesity facts 2020;13(5):514-527. doi:10.1159/000511023.
Parent A-S, Teilmann G, Juul A, Skakkebaek NE, Toppari J, Bourguignon J-P. The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends, and changes after migration. Endocr Rev. 2003;24(5):668-693. doi:10.1210/er.2002-0019.
Holmes DT, Buhr KA. Widespread incorrect implementation of the Hoffmann Method, the correct approach, and modern alternatives. Am J Clin Pathol. 2019;151(3):328-336. doi:10.1093/ajcp/aqy149.
Katayev A, Fleming JK, Holmes DT, Buhr KA. Widespread implementation of the Hoffmann Method: a second opinion. Am J Clin Pathol. 2019;152(1):116-117. doi:10.1093/ajcp/aqz015.
van Esdonk MJ, van Zutphen EJM, Roelfsema F, et al. How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review. Pituitary 2018;21(3):310-322. doi:10.1007/s11102-018-0884-4.
